Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications

(2010) Mickaël Hiligsmann et al.   CALCIFIED TISSUE INTERNATIONAL

Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures

(2009) Nianwen Shi et al.   BONE

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis

(2009) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

(2009) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Effectiveness of bisphosphonate therapy in a community setting

(2008) Adrianne C. Feldstein et al.   BONE

Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study

(2008) Darko Kastelan et al.   CLINICAL RHEUMATOLOGY

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)

(2008) Peyman Hadji et al.   JOINT BONE SPINE

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH